The patient was highly symptomatic despite the stable vision. Goldberg said a key takeaway for attendees was that “visual ...

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted ...

Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery ...

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Murtaza K. Adam, MD, reviews 3 patient cases to explore referral patterns, neovascularization after treatment, and barriers to care.

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.

An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual ...

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.

Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina ...

A simple stool test may reveal hidden bowel disease in patients whose only symptoms are in their eyes.

Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's ...